WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ...

Researchers have created an effective therapy for chronic pain that reduces pain intensity by focusing on emotional regulation.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025.

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...

DOTAGA.Glu.(FAPi) 2) has been in-licensed by Telix as part of a portfolio of next-generation therapeutic and diagnostic ("theranostic") radiopharmaceutical candidat ...

Q1 2025 Earnings Call Transcript May 6, 2025 Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $1.2 EPS, expectations were $1.38. Operator: Thank you for standing by, and welcome ...

The Society for Cardiovascular Angiography & Interventions (SCAI) recently announced the presentation of findings showing ...

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...